Suppr超能文献

2%睾酮溶液对性腺功能减退男性射精功能障碍的影响

Impact of Testosterone Solution 2% on Ejaculatory Dysfunction in Hypogonadal Men.

作者信息

Maggi Mario, Heiselman Darell, Knorr Jack, Iyengar Smriti, Paduch Darius A, Donatucci Craig F

机构信息

Department of Clinical Physiopathology, University of Florence, Florence, Italy.

Eli Lilly and Company, Indianapolis, IN, USA.

出版信息

J Sex Med. 2016 Aug;13(8):1220-6. doi: 10.1016/j.jsxm.2016.05.012.

Abstract

INTRODUCTION

Hypogonadism is defined as decreased testosterone levels in men. Hypogonadism can be accompanied by erectile, orgasmic, and ejaculatory dysfunction.

AIMS

To evaluate whether treatment with testosterone solution 2% (testosterone) could improve ejaculatory function in a cohort of hypogonadal men.

METHODS

Sexually active, hypogonadal men at least 18 years old (total testosterone < 300 ng/dL) were randomized to receive testosterone or placebo for 12 weeks.

MAIN OUTCOME MEASURES

Effects of testosterone on primary outcomes were evaluated using the International Index of Erectile Function (IIEF) and the Men's Sexual Health Questionnaire, Ejaculatory Dysfunction, Short Form (MSHQ-EjD-SF) questionnaires. Treatment differences were calculated using analysis of covariance.

RESULTS

In total, 715 men (mean age = 55 years) were randomized to placebo (n = 357) or testosterone (n = 358). Most sexually active men who reported IIEF scores had some degree of erectile dysfunction (IIEF erectile function score < 26). Although ejaculatory function score (MSHQ-EjD-SF) improved in the testosterone group compared with placebo (P < .001), improvement on the "bother" item did not reach statistical significance. Treatment-related adverse events in the testosterone group affecting at least 1% of patients were increased hematocrit, upper respiratory tract infection, arthralgia, burning sensation, fatigue, increased prostate-specific antigen, erythema, and cough. Few patients in either treatment group developed at least one adverse event leading to discontinuation (testosterone = 1.98% vs placebo = 3.09%; P = .475).

CONCLUSION

Hypogonadal men receiving testosterone solution 2% therapy experience significantly greater improvement in ejaculatory function, compared with placebo, as assessed by the MSHQ-EjD-SF. However, improvement in "bother" was not statistically different between the two groups. Testosterone therapy was generally well tolerated.

摘要

引言

性腺功能减退定义为男性睾酮水平降低。性腺功能减退可能伴有勃起、性高潮和射精功能障碍。

目的

评估2%睾酮溶液(睾酮)治疗能否改善一组性腺功能减退男性的射精功能。

方法

年龄至少18岁、有性活动的性腺功能减退男性(总睾酮<300 ng/dL)被随机分为接受睾酮或安慰剂治疗12周。

主要观察指标

使用国际勃起功能指数(IIEF)和男性性健康问卷射精功能障碍简表(MSHQ-EjD-SF)问卷评估睾酮对主要结局的影响。采用协方差分析计算治疗差异。

结果

总共715名男性(平均年龄=55岁)被随机分为安慰剂组(n = 357)或睾酮组(n = 358)。大多数报告IIEF评分的有性活动男性存在一定程度的勃起功能障碍(IIEF勃起功能评分<26)。虽然与安慰剂组相比,睾酮组的射精功能评分(MSHQ-EjD-SF)有所改善(P<.001),但“困扰”项目的改善未达到统计学意义。睾酮组中至少1%患者出现的与治疗相关的不良事件包括血细胞比容升高、上呼吸道感染、关节痛、烧灼感、疲劳、前列腺特异性抗原升高、红斑和咳嗽。两个治疗组中很少有患者出现至少一种导致停药的不良事件(睾酮组=1.98%,安慰剂组=3.09%;P=.475)。

结论

根据MSHQ-EjD-SF评估,与安慰剂相比,接受2%睾酮溶液治疗的性腺功能减退男性射精功能改善明显更大。然而,两组之间“困扰”方面的改善在统计学上无差异。睾酮治疗总体耐受性良好。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验